Onconetics Pharmaceuticals, Inc. engages in research and drug development for the emerging and highly sought-after field of personalized medicine in order to develop treatments for cancer and other genetic disorders. It combines well-established gene therapy techniques with pioneering research to create novel therapeutic outcomes that seek to change the highly invasive, costly, and uncertain nature of traditional therapies. Onconetics aims to create simpler, more versatile personalized therapies for cancer and genetic disorders that pose little or no risk to the patient and their quality of life, while pushing the frontiers of our understanding of the microscopic world.
Onconetics was founded by Luke Gruenert and Gabriel Hitchcock on November 3rd, 2016.
Location: United States, California, San Francisco
Mentions in press and media 1
|17.04.2018||Watch Indi...||Today, April 17th at 2:00 PT, ...||biotech, d...||Neesha A. ...||techcrunch...|